Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MYMD PHARMACEUTICALS, INC.

(MYMD)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

MYMD PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

09/13/2021 | 05:32pm EDT

Item 7.01 Regulation FD Disclosure.

On September 13, 2021, MyMD Pharmaceuticals, Inc. (the "Company") issued a press release, attached hereto as Exhibit 99.1, announcing that it intends to initiate dosing for a Phase 2 trial of MYMD-1's function in delaying aging early in the fourth quarter of 2021. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit
Number     Description
99.1         Press Release, dated September 13, 2021 (furnished herewith pursuant
          to Item 7.01)
104        Cover Page Interactive Data File (formatted as Inline XBRL)

© Edgar Online, source Glimpses

All news about MYMD PHARMACEUTICALS, INC.
10/05MYMD PHARMACEUTICALS : to launch two simultaneous Phase 2 trials during the current quarte..
PU
10/05MYMD PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
AQ
10/05MYMD PHARMACEUTICALS TO DETAIL ITS T : Catalytic Small Cap Growth Conference on October 7
BU
09/22MYMD PHARMACEUTICALS : Data indicates potential of drug candidate to deliver an extremely ..
PU
09/22MYMD PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
AQ
09/22MYMD PHARMACEUTICALS : Announces New Data Demonstrating 8,000 Times Higher Potency of Nove..
BU
09/22MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Nov..
CI
09/20MYMD PHARMACEUTICALS, INC.(NASDAQCM : MYMD) added to S&P Global BMI Index
CI
09/13MYMD PHARMACEUTICALS : Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial ..
PU
09/13MYMD PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
AQ
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -8,93 M - -
Net Debt 2020 2,89 M - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 295 M 295 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 6
Free-Float 86,7%
Chart MYMD PHARMACEUTICALS, INC.
Duration : Period :
MyMD Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MYMD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Christopher C. Chapman President, Director & Chief Medical Officer
Ian Rhodes Chief Financial Officer
Joshua Nathaniel Silverman Chairman
Adam Kaplin Chief Scientific Officer
Paul Rivard Executive VP-Operations & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
MYMD PHARMACEUTICALS, INC.98.24%295
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414